Cost‐effectiveness analysis of cabozantinib as second‐line therapy in advanced hepatocellular carcinoma

Wei‐Ting Liao(Kaohsiung Medical University), Qiu Li(Sichuan University)
Liver International
September 23, 2019
Cited by 50


Related Papers